OMER · Omeros Corp
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-22 | Cancelmo Peter B |
VP, General Counsel |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
One-third of the total number of shares subject to the option will vest and become exercisable on August 1, 2027. The remaining shares shall vest in 32 equal monthly installments on the first day of each month thereafter. |
Stock Option (right to buy)
|
105,000 |
| 2026-07-22 | Borges David J. |
VP, Finance & CAO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
One-third of the total number of shares subject to the option will vest and become exercisable on August 1, 2027. The remaining shares shall vest in 32 equal monthly installments on the first day of each month thereafter. |
Stock Option (right to buy)
|
105,000 |
| 2026-07-22 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
One-third of the total number of shares subject to the option will vest and become exercisable on August 1, 2027. The remaining shares shall vest in 32 equal monthly installments on the first day of each month thereafter. |
Stock Option (right to buy)
|
1,000,000 |
| 2026-06-18 | Cable Thomas J. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026. This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2026-06-18 | Demopulos Peter A MD |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026. This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2026-06-18 | Hood Leroy E. MD PhD |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026. This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2026-06-18 | HANISH ARNOLD C |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026. This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2026-06-18 | Perkinson Diana T. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026. This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2026-06-18 | Shah Rajiv |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026. This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2026-06-18 | Bumol Thomas F. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026. This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2026-05-22 | Cable Thomas J. |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Open market sale pursuant to a previously established Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2024. The trading schedule, including sale periods and the number of shares to be sold, was established at the time of the trading plan's adoption in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired upon the exercise of vested stock options scheduled to expire on June 9, 2026. This transaction was executed in multiple trades at prices ranging from $11.46 to $11.93. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. |
Common Stock
|
7,500 |
| 2026-05-22 | Cable Thomas J. |
Director |
Convert↑
|
Common Stock
|
7,500 |
| 2026-05-22 | Cable Thomas J. |
Director |
Convert↓
|
Stock Option (Right to Buy)
|
7,500 |
| 2026-02-18 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Convert↑
|
Common stock
|
400,000 |
| 2026-02-18 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Convert↓
Filing footnotes — Stock option (right to buy) (Direct)
This option vested and became exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2015. |
Stock option (right to buy)
|
400,000 |
| 2026-02-18 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Tax↓
Filing footnotes — Common stock (Direct)
Represents shares withheld by Omeros Corporation ("Omeros") in connection with net share settlement to satisfy the exercise price and tax liability associated with the reporting person's exercise of stock options. The number of shares withheld was determined based on the closing price of Omeros' common stock on February 17, 2026. The transaction did not involve any open-market sale of securities, and all 357,678 withheld shares remained in the Omeros treasury. |
Common stock
|
357,678 |
| 2026-01-13 | Borges David J. |
VP, Finance & CAO |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This option vests and becomes exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2024. Installments vest and become exercisable on each monthly anniversary thereafter. |
Stock Option (right to buy)
|
30,000 |
| 2026-01-13 | Borges David J. |
VP, Finance & CAO |
Convert↑
|
Common stock
|
30,000 |
| 2026-01-13 | Borges David J. |
VP, Finance & CAO |
Sell↓
Filing footnotes — Common stock (Direct)
This transaction was executed in multiple trades at prices ranging from $12.13 to $12.62. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. |
Common stock
|
30,000 |
| 2026-01-12 | Borges David J. |
VP, Finance & CAO |
Sell↓
Filing footnotes — Common stock (Direct)
This transaction was executed in multiple trades at prices ranging from $12.56 to $13.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. |
Common stock
|
30,000 |
| 2025-10-13 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Gift↑
Filing footnotes — Common Stock (Indirect)
The reporting person made bona fide gifts of Omeros Corporation common stock, each of 300,000 shares, to separate irrevocable trusts established for the benefit of each of the reporting person's two minor children. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and nothing in this report shall be deemed an admission that the reporting person is the beneficial owner of such securities under Section 16 of the Securities Exchange Act of 1934 or for any other purpose. Shares held in the [Demopulos Child #1] Gift Trust, an irrevocable trust established for the benefit of a minor child of the reporting person. |
Common Stock
(I)
|
300,000 |
| 2025-10-13 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Gift↓
Filing footnotes — Common Stock (Direct)
The reporting person made bona fide gifts of Omeros Corporation common stock, each of 300,000 shares, to separate irrevocable trusts established for the benefit of each of the reporting person's two minor children. |
Common Stock
|
600,000 |
| 2025-10-13 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Gift↑
Filing footnotes — Common Stock (Indirect)
The reporting person made bona fide gifts of Omeros Corporation common stock, each of 300,000 shares, to separate irrevocable trusts established for the benefit of each of the reporting person's two minor children. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and nothing in this report shall be deemed an admission that the reporting person is the beneficial owner of such securities under Section 16 of the Securities Exchange Act of 1934 or for any other purpose. Shares held in the [Demopulos Child #2] Gift Trust, an irrevocable trust established for the benefit of a minor child of the reporting person. |
Common Stock
(I)
|
300,000 |
| 2025-06-30 | Cancelmo Peter B |
VP, General Counsel |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2025. Installments vest and become exercisable on each monthly anniversary thereafter. |
Stock Option (right to buy)
|
100,000 |
| 2025-06-30 | Borges David J. |
VP, Finance & CAO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2025. Installments vest and become exercisable on each monthly anniversary thereafter. |
Stock Option (right to buy)
|
95,000 |
| 2025-06-30 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2025. Installments vest and become exercisable on each monthly anniversary thereafter. |
Stock Option (right to buy)
|
865,000 |
| 2025-06-27 | Cable Thomas J. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 27, 2025. This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2025-06-27 | HANISH ARNOLD C |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 27, 2025. This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2025-06-27 | Hood Leroy E. MD PhD |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 27, 2025. This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2025-06-27 | Perkinson Diana T. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 27, 2025. This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2025-06-27 | Shah Rajiv |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 27, 2025. This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2025-06-27 | Bumol Thomas F. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 27, 2025. This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2025-06-27 | Demopulos Peter A MD |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 27, 2025. This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2024-06-06 | Bumol Thomas F. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 6, 2024. This option will fully vest and become exercisable on the day before the date of the 2025 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2024-06-06 | Hood Leroy E. MD PhD |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 6, 2024. This option will fully vest and become exercisable on the day before the date of the 2025 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2024-06-06 | Perkinson Diana T. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 6, 2024. This option will fully vest and become exercisable on the day before the date of the 2025 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2024-06-06 | Shah Rajiv |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 6, 2024. This option will fully vest and become exercisable on the day before the date of the 2025 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2024-06-06 | Cable Thomas J. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 6, 2024. This option will fully vest and become exercisable on the day before the date of the 2025 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2024-06-06 | Demopulos Peter A MD |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 6, 2024. This option will fully vest and become exercisable on the day before the date of the 2025 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2024-06-06 | HANISH ARNOLD C |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 6, 2024. This option will fully vest and become exercisable on the day before the date of the 2025 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date. |
Stock Option (Right to Buy)
|
15,000 |
| 2024-04-25 | Cancelmo Peter B |
VP, General Counsel |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2024. Installments vest and become exercisable on each monthly anniversary thereafter. |
Stock Option (right to buy)
|
100,000 |
| 2024-04-25 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2024. Installments vest and become exercisable on each monthly anniversary thereafter. |
Stock Option (right to buy)
|
725,000 |
| 2024-04-25 | JACOBSEN MICHAEL A |
VP, Finance & CAO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2024. Installments vest and become exercisable on each monthly anniversary thereafter. |
Stock Option (right to buy)
|
100,000 |
| 2023-11-17 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Buy↑
Filing footnotes — Common Stock (Indirect)
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and nothing in this report shall be deemed an admission that the reporting person is the beneficial owner of such securities under Section 16 of the Securities Exchange Act of 1934 or for any other purpose. |
Common Stock
(I)
|
15,000 |
| 2023-11-15 | Demopulos Peter A MD |
Director |
Buy↑
|
Common Stock
|
10,000 |
| 2023-11-14 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Award↑
Filing footnotes — Common Stock (Indirect)
This transaction was executed in multiple trades at prices ranging from $1.43 to $1.45. The price reported above reflects the weighted average sales price.The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in thisfootnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and nothing in this report shall be deemed an admission that the reporting person is the beneficial owner of such securities under Section 16 of the Securities Exchange Act of 1934 or for any other purpose. |
Common Stock
(I)
|
25,000 |
| 2023-11-13 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Award↑
Filing footnotes — Common Stock (Indirect)
This transaction was executed in multiple trades at prices ranging from $1.26 to $1.30. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and nothing in this report shall be deemed an admission that the reporting person is the beneficial owner of such securities under Section 16 of the Securities Exchange Act of 1934 or for any other purpose. The shares reported herein include shares held by the reporting person's spouse with respect to which it was previously determined that the reporting person did not have an indirect pecuniary interest. |
Common Stock
(I)
|
37,500 |
| 2023-09-22 | Demopulos Gregory A MD |
Director, Chairman, CEO & President |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2023. Installments vest and become exercisable on each monthly anniversary thereafter. |
Stock Option (right to buy)
|
715,000 |
| 2023-09-22 | Cancelmo Peter B |
VP, General Counsel |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2023. Installments vest and become exercisable on each monthly anniversary thereafter. |
Stock Option (right to buy)
|
100,000 |
| 2023-09-22 | JACOBSEN MICHAEL A |
VP, Finance & CAO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option shall vest and become exercisable over 48 equal monthly installments, with a vesting commencement date of April 1, 2023. Installments vest and become exercisable on each monthly anniversary thereafter. |
Stock Option (right to buy)
|
100,000 |